Bloomberg Talks — Quest Diagnostics CEO Jim Davis Talks Outlook

Date: February 10, 2026
Host: Katie (Bloomberg)
Guest: Jim Davis (Quest Diagnostics CEO)

Episode Overview

This episode features an in-depth interview with Jim Davis, CEO of Quest Diagnostics. The discussion dives into Quest’s current growth drivers, the rising importance of consumer health and wellness, emerging trends in diagnostic testing such as Alzheimer's and oncology, and Quest’s strategy for business evolution. The conversation is focused on how diagnostics are shifting from chronic disease management to proactive prevention and the company’s innovations and partnerships in both arenas.

Key Discussion Points and Insights

1. Growth Drivers in Diagnostics

[00:37 - 02:03]

• Chronic Disease Management:

  • Chronic conditions like Type 2 diabetes, autoimmune disorders, and rising cancer rates (notably among younger populations) are increasing demand for diagnostic testing.
  • Diagnostics play a key role in not only identifying disease but guiding therapy selection and monitoring progression.

• Consumer Health & Wellness:

  • Prevention is a rapidly growing priority: consumers increasingly seek health data before symptoms arise.
  • Jim Davis highlights Quest’s partnerships with innovative health platforms (Function Health, Whoop, Aura) aiming to make lab testing accessible and routine for wellness-focused consumers.

Quote (Jim Davis, 01:14):
"Prevention is all about doing something before the symptoms set in... We are really powering the wellness industry today."

2. The Role & Growth of Consumer Health

[02:03 - 03:22]

• Financial Impact & Growth:

  • The consumer testing segment—including direct and partner channels—brought in around $250 million last year, out of $11 billion total revenue.
  • Despite its smaller share, this segment grew over 30% last year, with expectations of continued 20%+ growth.

• Business Transformation Aspirations:

  • Currently, about two-thirds of Quest’s business is related to diagnosing, treating, and monitoring disease; just a third is prevention and wellness.
  • Jim Davis expresses a strategic ambition: reverse this ratio over the next decade to focus predominantly on prevention and wellness.

Quote (Jim Davis, 03:11):
"Honestly, I hope over the next decade we can flip that. I really hope that we can be 2/3 prevention and wellness and then a third chronic care management."

3. Trends in Diagnostic Testing: Alzheimer’s and Early Detection

[03:22 - 04:46]

• Alzheimer’s Disease:
  • There is a significant shift toward using blood-based biomarkers (for amyloid plaque and tau) over traditional cognitive testing and imaging.
  • These blood-based tests offer earlier and more accessible detection, which is crucial for leveraging new therapies effective in early disease stages.
  • Access to memory care specialists is limited; these advances can accelerate diagnosis and treatment.

Quote (Jim Davis, 03:44):
"Today, what we're seeing is there’s blood based biomarkers... and you’re actually going to detect Alzheimer’s at a much earlier stage than what you would see in imaging."

4. Cancer and Oncology Testing

[04:46 - 06:00]

• Quest’s Oncology Portfolio:
  • Quest owns the largest anatomical pathology business in the U.S., providing cancer diagnoses from tissue samples daily.
  • Comprehensive post-diagnosis offerings include therapy selection and tests for minimal residual disease (MRD), through the Haystack Oncology acquisition.
  • MRD testing helps detect small amounts of remaining cancer post-treatment.
  • Testing for initial cancer detection also includes common screenings like PSA and various cancer markers.
  • Oncology accounts for roughly $1 billion of Quest’s $11 billion annual portfolio.

Quote (Jim Davis, 05:17):
"We have the largest anatomical pathology business in the country... and we have a test, you mentioned the Haystack, minimally residual disease testing that looks for very, very small remnants of the cancer that may remain either post surgery or post chemotherapy."

Notable Quotes

• On Health Prevention Focus:

  "Prevention is all about doing something before the symptoms set in."
  — Jim Davis, [01:14]

• On Company Vision for Prevention:

  "I hope over the next decade we can flip that. I really hope that we can be 2/3 prevention and wellness and a third chronic care management."
  — Jim Davis, [03:11]

• On Diagnostic Advances for Alzheimer’s:

  "You’re actually going to detect Alzheimer’s at a much earlier stage than what you would see in imaging."
  — Jim Davis, [03:44]

• On Quest’s Cancer Strategy:

  "We have the largest anatomical pathology business in the country...we make diagnoses of cancer every single day."
  — Jim Davis, [05:17]

Key Segments & Timestamps

• Growth drivers in diagnostics: [00:37 - 02:03]
• Consumer health partnerships & future goals: [02:03 - 03:22]
• Trends in test demand: Alzheimer's focus: [03:22 - 04:46]
• Oncology and cancer business strategy: [04:46 - 06:00]

Conclusion

Jim Davis’s conversation highlights Quest Diagnostics’ dual engines of growth: addressing the ongoing need for chronic disease management and rapidly expanding its position in consumer-focused, preventive health. He underscores that while prevention makes up a smaller slice of business now, Quest aims to make it the majority in the future, propelled by technological innovation, partnerships, and early detection—especially in areas like Alzheimer’s and cancer. The structural transformation of their business model is fundamentally about making healthcare more proactive, accessible, and patient-driven.